Recurrent Tuberculosis: Relapse, Reinfection, and HIV

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Feb 4

PMID 20121432

Citations 28

Authors

Richard E Chaisson

Gavin J Churchyard

Affiliations

Soon will be listed here.

Citing Articles

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort.

Amorim G, Jaworski J, Yang J, Cordeiro-Santos M, Kritski A, Figueiredo M Pharmacogenet Genomics. 2024; 35(2):55-64.

PMID: 39470346 PMC: 11695165. DOI: 10.1097/FPC.0000000000000552.

Timing of recurrence after treatment of pulmonary TB.

Mithunage C, Denning D IJTLD Open. 2024; 1(10):456-465.

PMID: 39398436 PMC: 11467853. DOI: 10.5588/ijtldopen.24.0222.

Decreased IL-1 β Secretion as a Potential Predictor of Tuberculosis Recurrence in Individuals Diagnosed with HIV.

Nosik M, Ryzhov K, Kudryavtseva A, Kuimova U, Kravtchenko A, Sobkin A Biomedicines. 2024; 12(5).

PMID: 38790916 PMC: 11117744. DOI: 10.3390/biomedicines12050954.

Helper T cell bias following tuberculosis chemotherapy identifies opportunities for therapeutic vaccination to prevent relapse.

Martinez-Martinez Y, Huante M, Chauhan S, Naqvi K, Bharaj P, Endsley J NPJ Vaccines. 2023; 8(1):165.

PMID: 37898618 PMC: 10613213. DOI: 10.1038/s41541-023-00761-4.

Global Stability for an Endogenous-Reactivated Tuberculosis Model with Beddington-DeAngelis Incidence, Distributed Delay and Relapse.

Sang Y, Zhang L, Song B, Zhang Y Qual Theory Dyn Syst. 2023; 22(3):89.

PMID: 37124842 PMC: 10123595. DOI: 10.1007/s12346-023-00788-x.

References

Small P, Shafer R, Hopewell P, Singh S, Murphy M, Desmond E . Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993; 328(16):1137-44. DOI: 10.1056/NEJM199304223281601. View

Barnard M, Albert H, Coetzee G, OBrien R, Bosman M . Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008; 177(7):787-92. DOI: 10.1164/rccm.200709-1436OC. View

Korenromp E, Scano F, Williams B, Dye C, Nunn P . Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis. 2003; 37(1):101-12. DOI: 10.1086/375220. View

Rosenthal I, Zhang M, Williams K, Peloquin C, Tyagi S, Vernon A . Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007; 4(12):e344. PMC: 2140085. DOI: 10.1371/journal.pmed.0040344. View

Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C . Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr. 2009; 50(2):148-52. DOI: 10.1097/QAI.0b013e31819367e7. View

Fitzgerald D, Desvarieux M, Severe P, Joseph P, Johnson Jr W, Pape J . Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet. 2000; 356(9240):1470-4. DOI: 10.1016/S0140-6736(00)02870-1. View

Golub J, Durovni B, King B, Cavalacante S, Pacheco A, Moulton L . Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2008; 22(18):2527-33. PMC: 2603140. DOI: 10.1097/QAD.0b013e328311ac4e. View

Sterling T, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai W . Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999; 13(14):1899-904. DOI: 10.1097/00002030-199910010-00012. View

Nahid P, Gonzalez L, Rudoy I, de Jong B, Unger A, Kawamura L . Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007; 175(11):1199-206. PMC: 1899273. DOI: 10.1164/rccm.200509-1529OC. View

10.

Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, Lalloo U . Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547):1575-80. DOI: 10.1016/S0140-6736(06)69573-1. View

11.

Verver S, Warren R, Beyers N, Richardson M, van der Spuy G, Borgdorff M . Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005; 171(12):1430-5. DOI: 10.1164/rccm.200409-1200OC. View

12.

Sonnenberg P, Murray J, Glynn J, Shearer S, Kambashi B, Godfrey-Faussett P . HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001; 358(9294):1687-93. DOI: 10.1016/S0140-6736(01)06712-5. View

13.

Corbett E, Bandason T, Cheung Y, Makamure B, Dauya E, Munyati S . Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis. 2009; 13(10):1231-7. PMC: 3374846. View

14.

Mostowy S, Tsolaki A, Small P, Behr M . The in vitro evolution of BCG vaccines. Vaccine. 2003; 21(27-30):4270-4. DOI: 10.1016/s0264-410x(03)00484-5. View

15.

Vernon A, Burman W, Benator D, Khan A, Bozeman L . Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999; 353(9167):1843-7. DOI: 10.1016/s0140-6736(98)11467-8. View

16.

Churchyard G, Fielding K, Charalambous S, Day J, Corbett E, Hayes R . Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?. AIDS. 2003; 17(14):2063-70. DOI: 10.1097/00002030-200309260-00007. View

17.

Barker L, Brennan M, Rosenstein P, Sadoff J . Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol. 2009; 21(3):331-8. DOI: 10.1016/j.coi.2009.05.017. View

18.

Charalambous S, Grant A, Moloi V, Warren R, Day J, van Helden P . Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis. 2008; 12(8):942-8. View